Table 2.
Details of patient characteristics, results of each PET imaging, and reference criteria for the final diagnosis in patients with non-glioma tumors and non-neoplastic lesions
| Pt. No. | Age range (y) | Locationa | FDG | NH3 | MET | Method of diagnosis | Final diagnosis | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Visual | L/WMb | Visual | L/WM | Visual | L/WM | |||||
| Non-glioma tumors | ||||||||||
| 1 | 50–55 | Cerebellum | (+) | 2.24 | (+) | 1.72 | (+) | 2.89 | Operation | Metastatic adenocarcinoma |
| 2 | 20–25 | L. basal ganglia region | (−) | 1.32 | (+) | 2.67 | (+) | 3.24 | Biopsy | Germinoma |
| 3 | 35–40 | R. cavernous sinus area | (+) | 2.38 | (+) | 2.30 | (+) | 3.35 | Operation | Squamous cell carcinoma |
| 4 | 40–45 | Suprasellar | (−) | 1.07 | (+) | 2.42 | (+) | 2.28 | Operation | Craniopharyngioma |
| 5 | 65–70 | R. parietal | (−) | 1.37 | (+) | 3.75 | (+) | 2.72 | Operation | Meningioma |
| 6 | 60–65 | Cerebellum | (−) | 1.28 | (+) | 3.66 | (+) | 2.78 | Operation | Hemangioblastoma |
| 7 | 25–30 | Cerebellum | (+) | 2.61 | (+) | 2.00 | (+) | 2.00 | Operation | Medulloblastoma |
| 8 | 25–30 | Cerebellum | (+) | 2.32 | (+) | 2.40 | (+) | 2.24 | Operation | Medulloblastoma |
| 9 | 45–50 | L. frontal | (+) | 4.02 | (+) | 3.09 | (+) | 3.00 | Operation | Metastatic tumor |
| 10 | 30–35 | R. frontal | (−) | 1.22 | (−) | 1.60 | (+−) | 1.51 | Operation | DNT |
| Non-neoplastic lesions | ||||||||||
| 11 | 20–25 | L. frontal | (+) | 2.75 | (+−) | 1.68 | (+−) | 1.58 | Follow-up | Inflammation |
| 12 | 40–45 | L. frontal-parietal | (−) | 1.76 | (−) | 1.10 | (−) | 1.00 | Biopsy | Demyelination |
| 13 | 30–35 | R. parietal | (+−) | 2.10 | (+−) | 1.64 | (+) | 2.27 | Follow-up | Demyelination |
| 14 | 25–30 | R. basal ganglia region | (+−) | 2.12 | (+−) | 1.72 | (+−) | 1.50 | Biopsy | Demyelination |
| 15 | 70–75 | Cervical spinal | (+) | 2.88 | (+−) | 1.70 | (+−) | 1.78 | Follow-up | Inflammation |
| 16 | 20–25 | R. cerebellopontine angle | (−) | 1.32 | (+−) | 1.63 | (+−) | 1.55 | Follow-up | Demyelination |
| 17 | 25–30 | R. thalamus | (−) | 1.80 | (+−) | 1.75 | (+−) | 1.77 | Follow-up | Inflammation |
| 18 | 40–45 | R. parietal | (+) | 2.23 | (+−) | 1.72 | (+) | 2.49 | Biopsy | Inflammation |
| 19 | 35–40 | R. cerebellum | (+) | 2.80 | (−) | 1.45 | (−) | 1.38 | Follow-up | Inflammation |
| 20 | 40–45 | Brain stem, R. temporal | (−) | 1.58 | (−) | 1.55 | (+−) | 1.54 | Follow-up | Inflammation |
| 21 | 40–45 | L. pons | (−) | 1.56 | (−) | 1.29 | (−) | 1.31 | Follow-up | Infarction |
| 22 | 50–55 | L. temporal | (+) | 2.49 | (−) | 0.94 | (+) | 2.67 | Operation | Brain abscess |
| 23 | 45–50 | L. parietal | (+) | 3.28 | (−) | 1.63 | (+) | 2.88 | Operation | Brain abscess |
| 24 | 40–45 | R. frontal | (+) | 3.80 | (−) | 1.58 | (+) | 3.04 | Operation | Brain abscess |
| 25 | 20–25 | L. parietal | (−) | 1.10 | (−) | 1.18 | (−) | 1.32 | Biopsy | Demyelination |
| 26 | 30–35 | L. basal ganglia region | (−) | 1.44 | (−) | 1.45 | (−) | 1.40 | Follow-up | Multiple sclerosis |
| 27 | 40–45 | R. cerebellum | (−) | 1.98 | (+−) | 1.79 | (+) | 2.60 | Follow-up | Infarction |
| 28 | 50–55 | L. frontal | (+−) | 2.10 | (+−) | 1.75 | (+) | 1.95 | Biopsy | Inflammation |
| 29 | 78–80 | R. parietal | (−) | 1.06 | (−) | 1.14 | (+) | 1.86 | Follow-up | Hemorrhage |
| 30 | 40–45 | L. frontal and parietal | (+) | 2.70 | (+) | 1.87 | (+) | 3.15 | Biopsy | Inflammation |
| 31 | 40–45 | Pons | (−) | 1.68 | (−) | 1.54 | (−) | 1.38 | Follow-up | Brain abscess |
| 32 | 50–55 | R. basal ganglia region | (−) | 1.58 | (−) | 1.02 | (+) | 1.81 | Follow-up | Infarction |
| 33 | 25–30 | L. thalamus | (−) | 1.52 | (−) | 1.44 | (−) | 1.15 | Biopsy | Demyelination |
a R right, L left, b L/WM Lesion-to-white matte ratio, DNT dysembryoplastic neuroepithelial tumor